We partner with leading clinical researchers and laboratory professionals to deliver breakthrough after breakthrough. Each one helps improve care for millions of patients living with autoimmune diseases through enhanced quality and efficiency.
What’s our latest breakthrough?
QUANTA Flash HMGCR help diagnose a form of statin-associated necrotizing myopathy which is positive by anti-HMGCR and not usually detected by other myopathy/myositis biomarkers.
How are we advancing the quality and efficiency of autoimmune testing?
NOVA Lite DAPI reagents, used in combination with NOVA View, provide improved quality for IFA testing with an automated process that can reduce labor hours and hands-on time in the lab.
How do we increase detection rates for APS?
QUANTA Lite anti-PS/PT is designed to increase detection rates for diagnosing APS by improving sensitivity, without sacrificing specificity. It can even be used to aid diagnosis when patients have already started treatment with anti-coagulation therapy.
Join our luncheon seminar at AMLI
Reducing Diagnostic Complexity with New Biomarkers
New markers hold great potential to improve care of Autoimmune diseases. We will discuss the advent of new markers for Connective Tissue Disease, Rheumatoid Arthritis, Antiphospholipid Syndrome, Myositis and Autoimmune Liver Disease which help close the seronegative gap. We will present an advanced technology for multi-analyte testing in Autoimmunity.
OUR LATEST INNOVATIONS
QUANTA-Lyser 3000 is a high throughput EIA/IFA that give you the ability to complete your workload faster with less hands-on time. That equates to maximum efficiency with increased productivity, all while safeguarding reagent and patient traceability to ensure integrity of results.
It All Starts With People
Our talent is, without a question, our most important asset. Our employees are the face of Inova, and they represent our values in their day-to-day interactions with our stakeholders